BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Elsberger B, Lankston L, McMillan DC, Underwood MA, Edwards J. Presence of tumoural C-reactive protein correlates with progressive prostate cancer. Prostate Cancer Prostatic Dis 2011;14:122-8. [PMID: 21358753 DOI: 10.1038/pcan.2011.5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Kim Y, Jeon Y, Lee H, Lee D, Shim B. The Prostate Cancer Patient Had Higher C-Reactive Protein Than BPH Patient. Korean J Urol 2013;54:85-8. [PMID: 23549045 DOI: 10.4111/kju.2013.54.2.85] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
2 Fang S, Wang Y, Sui D, Liu H, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Schacherer CW, Gardner JM, Reveille JD, Bassett RL, Wang LE, Wei Q, Amos CI, Lee JE. C-reactive protein as a marker of melanoma progression. J Clin Oncol 2015;33:1389-96. [PMID: 25779565 DOI: 10.1200/JCO.2014.58.0209] [Cited by in Crossref: 46] [Cited by in F6Publishing: 20] [Article Influence: 6.6] [Reference Citation Analysis]
3 Moyad MA, Klotz LH. Statin Clinical Trial (REALITY) for prostate cancer: an over 15-year wait is finally over thanks to a dietary supplement. Urol Clin North Am 2011;38:325-31. [PMID: 21798395 DOI: 10.1016/j.ucl.2011.05.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
4 Liu ZQ, Chu L, Fang JM, Zhang X, Zhao HX, Chen YJ, Xu Q. Prognostic role of C-reactive protein in prostate cancer: a systematic review and meta-analysis. Asian J Androl. 2014;16:467-471. [PMID: 24589465 DOI: 10.4103/1008-682x.123686] [Cited by in Crossref: 35] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
5 Jensen GL, Naziri J, Hammonds KP, Jhavar SG, Swanson G. C-Reactive Protein Is a Poor Marker of Baseline Inflammation in Prostate Cancer and Response to Radiotherapy or Androgen Ablation. Cureus 2021;13:e19639. [PMID: 34926085 DOI: 10.7759/cureus.19639] [Reference Citation Analysis]
6 Stikbakke E, Richardsen E, Knutsen T, Wilsgaard T, Giovannucci EL, McTiernan A, Eggen AE, Haugnes HS, Thune I. Inflammatory serum markers and risk and severity of prostate cancer: The PROCA-life study. Int J Cancer 2020;147:84-92. [PMID: 31583707 DOI: 10.1002/ijc.32718] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
7 Graff JN, Beer TM, Liu B, Sonpavde G, Taioli E. Pooled Analysis of C-Reactive Protein Levels and Mortality in Prostate Cancer Patients. Clinical Genitourinary Cancer 2015;13:e217-21. [DOI: 10.1016/j.clgc.2015.01.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
8 Kacevska M, Mahns A, Sharma R, Clarke SJ, Robertson GR, Liddle C. Extra-hepatic cancer represses hepatic drug metabolism via interleukin (IL)-6 signalling. Pharm Res 2013;30:2270-8. [PMID: 23604979 DOI: 10.1007/s11095-013-1042-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
9 Shrotriya S, Walsh D, Bennani-Baiti N, Thomas S, Lorton C. C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review. PLoS One 2015;10:e0143080. [PMID: 26717416 DOI: 10.1371/journal.pone.0143080] [Cited by in Crossref: 113] [Cited by in F6Publishing: 116] [Article Influence: 16.1] [Reference Citation Analysis]
10 Graff JN, Beer TM. The role of C-reactive protein in prostate cancer. Cancer 2013;119:3262-4. [PMID: 23817779 DOI: 10.1002/cncr.28211] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
11 Shastri BR, Yaturu S. Metabolic complications and increased cardiovascular risks as a result of androgen deprivation therapy in men with prostate cancer. Prostate Cancer 2011;2011:391576. [PMID: 22110984 DOI: 10.1155/2011/391576] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
12 Markt SC, Rider JR, Penney KL, Schumacher FR, Epstein MM, Fall K, Sesso HD, Stampfer MJ, Mucci LA. Genetic variation across C-reactive protein and risk of prostate cancer. Prostate 2014;74:1034-42. [PMID: 24844401 DOI: 10.1002/pros.22820] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
13 Roxburgh CS, Mcmillan DC. Therapeutics targeting innate immune/inflammatory responses through the interleukin-6/JAK/STAT signal transduction pathway in patients with cancer. Translational Research 2016;167:61-6. [DOI: 10.1016/j.trsl.2015.08.013] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
14 Ziaran S, Goncalves FM, Breza J Sr. Patients with prostate cancer treated by ADT have significantly higher fibrinogenemia than healthy control. World J Urol 2013;31:289-92. [PMID: 22898989 DOI: 10.1007/s00345-012-0926-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
15 Shafique K, Proctor MJ, McMillan DC, Leung H, Smith K, Sloan B, Morrison DS. The modified Glasgow prognostic score in prostate cancer: results from a retrospective clinical series of 744 patients. BMC Cancer 2013;13:292. [PMID: 23768149 DOI: 10.1186/1471-2407-13-292] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]